Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H32FN9O2 |
Molecular Weight | 533.6015 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1cc(=Nc2cc(C)[nH]n2)[nH]c([C@@]3([H])CC[C@](CC3)(C(=N[C@@]([H])(C)c4ccc(nc4)-n5cc(cn5)F)O)OC)n1
InChI
InChIKey=GBLBJPZSROAGMF-BATDWUPUSA-N
InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27-/m0/s1
Molecular Formula | C27H32FN9O2 |
Molecular Weight | 533.6015 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 12:57:54 UTC 2021
by
admin
on
Sat Jun 26 12:57:54 UTC 2021
|
Record UNII |
1WPE73O1WV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
634318
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
||
|
FDA ORPHAN DRUG |
728519
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2097132-94-8
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
129073603
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
C132295
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
2394936
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
SUB196574
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
11004
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
Pralsetinib
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY | |||
|
1WPE73O1WV
Created by
admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
Protein binding of pralsetinib is independent of concentration.
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
MULTIPLE DOSES |
|
||
Tmax | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||